An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Simulations Plus to Host Investor Day on Tuesday, November 14th
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Simulations Plus, Inc. (Nasdaq: SLP) will hold a virtual Investor Day on November 14, 2023. CEO Shawn O’Connor and the leadership team will discuss customer-driven growth and innovation. Attendance is by invitation only. Dial-in information will be provided later. Webcast, replay, and transcript will be available on the company's website.
Positive
None.
Negative
None.
LANCASTER, Calif.--(BUSINESS WIRE)--
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that it will hold a virtual Investor Day on Tuesday, November 14, 2023, beginning at 1:00 p.m. Eastern time. Presentations will be given by CEO Shawn O’Connor and members of the Simulations Plus leadership team who will share how putting customers first drives growth and fuels innovation.
This event will be virtual, and attendance is by invitation only. Dial-in information will be available at a later date, and a more detailed agenda, presentations and a live webcast will be available on the day of the event on the Simulations Plus website at https://www.simulations-plus.com/investorscorporate-profile/conference-calls/. A replay and transcript of the webcast will be available shortly after the event.
About Simulations Plus, Inc.
Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge artificial intelligence (AI)/machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | Twitter | YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our ESG website.
When will Simulations Plus hold its virtual Investor Day?
Simulations Plus will hold its virtual Investor Day on November 14, 2023.
Who will be giving presentations at the Investor Day?
CEO Shawn O’Connor and members of the Simulations Plus leadership team will be giving presentations.
What will be the focus of the presentations?
The presentations will focus on how putting customers first drives growth and fuels innovation.
How can I attend the Investor Day?
Attendance is by invitation only. Dial-in information will be provided at a later date.
Where can I find more information about the event?
A more detailed agenda, presentations, and a live webcast will be available on the day of the event on the Simulations Plus website at https://www.simulations-plus.com/investorscorporate-profile/conference-calls/.
Will there be a replay and transcript of the webcast?
Yes, a replay and transcript of the webcast will be available shortly after the event.
simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res
